StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.71−2.74 (-2.55%)

Close on Nov 17, 2026Market cap $181.19BP/E 33.7Yield 2.29%

Abbott Laboratories total assets

Total assets on the balance sheet at the end of each period.

Abbott Laboratories's total assets was $109.22B at Jun 30, 2026. For fiscal 2025 it was $86.71B, up 6.5% from the year before. Over ten years it grew 7.7% a year on average. The highest annual figure on record is $86.71B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$86.71B+6.5%
FY2024Dec 31, 2024$81.41B+11.2%
FY2023Dec 31, 2023$73.21B-1.6%
FY2022Dec 31, 2022$74.44B-1.0%
FY2021Dec 31, 2021$75.20B+3.6%
FY2020Dec 31, 2020$72.55B+6.9%
FY2019Dec 31, 2019$67.89B+1.1%
FY2018Dec 31, 2018$67.17B-11.9%
FY2017Dec 31, 2017$76.25B+44.8%
FY2016Dec 31, 2016$52.67B+27.7%
FY2015Dec 31, 2015$41.25B+0.1%
FY2014Dec 31, 2014$41.21B-4.0%
FY2013Dec 31, 2013$42.94B-36.1%
FY2012Dec 31, 2012$67.24B+11.5%
FY2011Dec 31, 2011$60.28B-0.5%
FY2010Dec 31, 2010$60.57B+15.2%
FY2009Dec 31, 2009$52.58B+24.0%
FY2008Dec 31, 2008$42.42B+6.8%
FY2007Dec 31, 2007$39.71B–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$109.22B+30.0%
Q1 FY2026Mar 31, 2026$110.43B+35.6%
Q4 FY2025Dec 31, 2025$86.71B+6.5%
Q3 FY2025Sep 30, 2025$84.18B+13.2%
Q2 FY2025Jun 30, 2025$84.00B+15.0%
Q1 FY2025Mar 31, 2025$81.45B+12.4%
Q4 FY2024Dec 31, 2024$81.41B+11.2%
Q3 FY2024Sep 30, 2024$74.36B+3.1%
Q2 FY2024Jun 30, 2024$73.02B-0.5%
Q1 FY2024Mar 31, 2024$72.47B-1.8%
Q4 FY2023Dec 31, 2023$73.21B-1.6%
Q3 FY2023Sep 30, 2023$72.09B-1.0%
Q2 FY2023Jun 30, 2023$73.35B-1.1%
Q1 FY2023Mar 31, 2023$73.79B-0.3%
Q4 FY2022Dec 31, 2022$74.44B-1.0%
Q3 FY2022Sep 30, 2022$72.80B-1.3%
Q2 FY2022Jun 30, 2022$74.20B+1.3%
Q1 FY2022Mar 31, 2022$74.01B+1.7%
Q4 FY2021Dec 31, 2021$75.20B+3.6%
Q3 FY2021Sep 30, 2021$73.80B+6.9%
Q2 FY2021Jun 30, 2021$73.27B+6.5%
Q1 FY2021Mar 31, 2021$72.79B+9.0%
Q4 FY2020Dec 31, 2020$72.55B+6.9%
Q3 FY2020Sep 30, 2020$69.04B+0.7%
Q2 FY2020Jun 30, 2020$68.78B+0.5%
Q1 FY2020Mar 31, 2020$66.78B-1.2%
Q4 FY2019Dec 31, 2019$67.89B+1.1%
Q3 FY2019Sep 30, 2019$68.54B-4.3%
Q2 FY2019Jun 30, 2019$68.43B+0.0%
Q1 FY2019Mar 31, 2019$67.61B-4.7%
Q4 FY2018Dec 31, 2018$67.17B-11.9%
Q3 FY2018Sep 30, 2018$71.64B-0.8%
Q2 FY2018Jun 30, 2018$68.42B-3.8%
Q1 FY2018Mar 31, 2018$70.91B+0.0%
Q4 FY2017Dec 31, 2017$76.25B+44.8%
Q3 FY2017Sep 30, 2017$72.25B+82.9%
Q2 FY2017Jun 30, 2017$71.15B–
Q1 FY2017Mar 31, 2017$70.89B–
Q4 FY2016Dec 31, 2016$52.67B–
Q3 FY2016Sep 30, 2016$39.50B–

More Abbott Laboratories figures

See a number that looks wrong?